1. Home
  2. VRDN

VRDN

Viridian Therapeutics Inc.

Logo Viridian Therapeutics Inc.

Health Care

Medical Specialities

Nasdaq

as 04-18-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Founded: 2006 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 946.5M IPO Year: N/A
Target Price: $37.80 AVG Volume (30 days): 919.6K
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -5.31 EPS Growth: N/A
52 Week Low/High: $10.93 - $30.30 Next Earning Date: 05-07-2024
Revenue: $314,000 Revenue Growth: -82.28%
Revenue Growth (this year): -13% Revenue Growth (next year): 2600.45%

Share on Social Networks: